Pharmaceutical Technology Editors

USP releases new and revised standards for organic impurities in medicines for public comment.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Agenus and Merck work together to advance immune-oncology programs.

TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.

The European Medicines Agency's Annual Report highlights drug approvals, projects, and initiatives for 2013.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

Colorcon invests in significant expansion of its South Asia production facility.

Pfizer and AstraZeneca admit to merger discussions, state positions to stakeholders.

Capsugel enters an agreement with Chiasma to increase manufacturing operations for octreotide, a treatment for acromegaly.

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

ISPE drug shortage prevention plan to address organizational strategies, manufacturing and quality systems, and supply chain quality.

INTERPEHX 2014 attendees tested their driving skills in a racecar simulator at the Federal Equipment booth.

CPhI report warns industry must actively drive process improvements to meet growing global demand for pharmaceuticals.

Spectrum Pharmaceuticals appoints Joseph Turgeon as president and COO.

Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.

Rommelag continues to supply blow-fill-seal machinery, with the brand name bottelpack.

Eli Lilly will acquire Novartis Animal Health for approximately $5.4 billion.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Cubist Pharmaceuticals issues voluntary nationwide recall of one lot of CUBICIN single use vials due to presence of particulate matter.

Roquette America and Quadra Ingredients enter a partnership for the distribution of pharmaceutical products in Canada.

Hospira announces nationwide voluntary recall of propofol injectable emulsion, USP, and lidocaine HCI injection, USP due to visible particuluates.

Thomson Reuters names three potential drugs anticipated to bring in over $1 billion in sales through 2019.

BASF builds a new plant for specialty amines in Ludwigshafen, Germany.

GSK receives FDA approval of Tanzeum for adults with type 2 diabetes.

AMRI will close its DDS facility in Syracuse, NY.

EMA notifies EU healthcare professionals of the falsified cancer drug Herceptin.

Mallinckrodt will acquire Questcor to create a diversified, high-growth specialty pharmaceuticals company.

Metrohm appoints Edward Colihan as president and CEO of Metrohm USA.

EMA sends its results on Roche investigation of pharmacovigilance non-compliance to the European Commission.

ThioBridge linker technology to attach different payloads to a range of antibodies